• linkedin
  • Increase Font
  • Sharebar

    The latest in biocellular regeneration

    Dr. HoffmanRepliCel Life Sciences made three announcements in 2017 regarding successful phase 1 studies of its novel skin and hair regenerative therapies and that they’ve secured a U.S. patent for a technology to deliver those investigational therapies. 

    In March, the Vancouver-based company announced its pipeline autologous cell therapy, RCH-01, for treatment of male and female androgenetic alopecia, successfully completed a phase 1 clinical trial for hair loss, establishing the product’s safety and showing promising signs of stabilizing further hair loss and increasing hair density.

    RepliCel’s RCS-01 autologous cell therapy, aimed at reversing the effects of skin aging and sun damage, also delivered successful safety results in a phase I skin trial. It significantly impacted biomarkers scientifically correlated with collagen production — a factor highly associated with skin rejuvenation, according to an April 4 company news release.

    And in late April, the company announced they were issued a U.S. patent for their multi-needle dermal injection device. The technology, if it pans out in studies, will be used along with RepliCel’s proprietary cell therapy products targeting pattern baldness and aging or UV-damaged skin, as well as for other injectable products.

    Rolf Hoffmann, M.D., RepliCel’s chief medical officer and a dermatologist by training, describes RCS-01 as a therapy that uses specific fibroblasts from the skin, under the hair.

    “These fibroblasts come from the dermal sheath, which is the specific structure around the hair. The hairs are harvested from the back of the head. By definition, those hairs and consequently those fibroblasts have never seen UV light, so they are UV naïve. These cells, by their nature, make more collagen than the surrounding skin fibroblasts,” Dr. Hoffmann says.

    The process involves harvesting and culturing those UV-naïve cells and injecting them back into UV damaged skin — especially the cheeks, neck, décolleté and backs of hands. Conceptually, the autologous cells should diminish fine wrinkles and make more collagen in the injected area, he says. 

    NEXT: Skin, Hair Technology

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available